Sequence variations of microRNAs in human cancer: Alterations in predicted secondary structure do not affect processing

Cancer Research

Volumn 66, Issue 12, 2006, Pages 6097-6104

  Diederichs, Sven ^a   Haber, Daniel A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; RAS PROTEIN;

ARTICLE; CANCER CELL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DEACETYLATION; DNA METHYLATION; DNA POLYMORPHISM; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CANCER; PRIORITY JOURNAL; RNA SEQUENCE;

ACETYLATION; BASE SEQUENCE; CELL LINE, TUMOR; DNA METHYLATION; GENE EXPRESSION PROFILING; HISTONES; HUMANS; LUNG NEOPLASMS; MICRORNAS; NEOPLASMS; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33745700209     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0537     Document Type: Article

References (42)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
2. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003;425:415-9.
3. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003;17:3011-6.
4. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 2001;293:834-8.
5. Grishok A, Pasquinelli AE, Conte D, et al. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell 2001;106:23-34.
6. Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, Plasterk RH. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev 2001;15:2654-9.
7. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005;433:769-73.
8. Lewis BP, Shin IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003;115:787-98.
9. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human microRNA targets. PLoS Biol 2004;2:e363.
10. Krek A, Grun D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet 2005;37:495-500.
11. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.
12. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-33.
13. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005;435:839-43.
14. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-47.
15. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753-6.
16. Calin GA, Ferracin M, Cimmino A, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353:1793-801.
17. Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000;403:901-6.
18. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999-3004.
19. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002;99:15524-9.
20. Borkhardt A, Fuchs U, Tuschl T. MicroRNA in chronic lymphocytic leukemia. N Engl J Med 2006;354:524-5; author reply 525.
21. Gius D, Cui H, Bradbury CM, et al. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 2004;6:361-71.
22. Goff LA, Yang M, Bowers J, Getts RC, Padgett RW, Hart RP. Rational probe optimization and enhanced detection strategy for microRNAs using microarrays. RNA Biology 2005;2:e9-16.
23. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
24. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 2003;31:3406-15.
25. Michael MZ, SM OC, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific micro-RNAs in colorectal neoplasia. Mol Cancer Res 2003;1:882-91.
26. Wistuba H, Behrens C, Virmani AK, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoptastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss, and three regions of frequent breakpoints. Cancer Res 2000;60:1949-60.
27. Aboulkassim TO, LaRue H, Lemieux P, Rousseau F, Fradet Y. Alteration of the PATCHED locus in superficial bladder cancer. Oncogene 2003;22:2967-71.
28. Simoneau M, Aboulkassim TO, LaRue H, Rousseau F, Fradet Y. Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31. Oncogene 1999;18:157-63.
29. Rasio D, Negrini M, Manenti G, Dragani TA, Croce CM. Loss of heterozygosity at chromosome 11q in lung adenocarcinoma: identification of three independent regions. Cancer Res 1995;55:3988-91.
30. Launonen V, Stenback F, Puistola U, et al. Chromosome 11q22.3-q25 LOH in ovarian cancer: association with a more aggressive disease course and involved subregions. Gynecol Oncol 1998;71:299-304.
31. Pulido HA, Fakruddin MJ, Chatterjee A, et al. Identification of a 6-cM minimal deletion at 11q23.1-23.2 and exclusion of PPP2R1B gene as a deletion target in cervical cancer. Cancer Res 2000;60:6677-82.
32. Kohno T, Kawanishi M, Matsuda S, et al. Homozygous deletion and frequent allelic loss of the 21q11.1-q21.1 region including the ANA gene in human lung carcinoma. Genes Chromosomes Cancer 1998;21:236-43.
33. Boultwood J, Strickson AJ, Jabs EW, Cheng JF, Fidler C, Wainscoat JS. Physical mapping of the human ATX1 homologue (HAH1) to the critical region of the 5q-syndrome within 5q32, and immediately adjacent to the SPARC gene. Hum Genet 2000;106:127-9.
34. Brown D, Shingara J, Keiger K, et al. Cancer-related miRNAs uncovered by the mirVana™ miRNA microarray platform. Ambion TechNotes 2005;12:8-11.
35. Protopopov A, Kashuba V, Zabarovska VI, et al. An integrated physical and gene map of the 3.5-Mb chromosome 3p21.3 (AP20) region implicated in major human epithelial malignancies. Cancer Res 2003;63:404-12.
36. Saito-Ohara F, Imoto I, Inoue J, et al. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 2003;63:1876-83.
37. Iwai N, Naraba H. Polymorphisms in human pre-miRNAs. Biochem Biophys Res Commun 2005;331:1439-44.
38. Zeng Y, Yi R, Cullen BR. Recognition and cleavage of primary microRNA precursors by the nuclear processing enzyme Drosha. EMBO J 2005;24:138-48.
39. Zeng Y, Cullen BR. Efficient processing of primary microRNA hairpins by Drosha requires flanking nonstructured RNA sequences. J Biol Chem 2005;280:27595-603.
40. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 2006;66:1277-81.
41. Yang W, Chendrimada TP, Wang Q, et al. Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat Struct Mol Biol 2006;13:13-21.
42. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98.